REV1 Antibody

1. These data indicate that dysregulation of cellular Rev1 levels leads to the accumulation of mutations and suppression of cell death, which accelerates the tumorigenic activities of DNA-damaging agents. PMID: 28498946
2. The data directly show that, in the human genome, DNA Pol-eta and Rev1 bypass cyclobutane pyrimidine dimers and 6-4PP at replication forks, while only 6-4PP are also tolerated by a Rev3L-dependent gap-filling mechanism, independent of S phase. PMID: 27095204
3. the catalytic function of REV1 is moderately or slightly altered by at least nine genetic variations, and the G4 DNA processing function of REV1 is slightly enhanced by the N373S variation, which might provide the possibility that certain germline missense REV1 variations affect the individual susceptibility to carcinogenesis by modifying the capability of REV1 for replicative bypass past DNA lesions and G4 motifs derived PMID: 26914252
4. REV1 can promote PCNA monoubiquitylation after UV radiation through interacting with ubiquitylated RAD18. PMID: 26795561
5. Saccharomyces cerevisiae PMID: 26903512
6. Rev1 is indispensable for Translesion synthesis mediated by Poleta, Poliota, and Polkappa but is not required for TLS by Polzeta. PMID: 26680302
7. Data suggest Rev1 protein recognition mechanism by Fanconi anemia-associated protein 20 (FAAP20). PMID: 26318859
8. show that REV1 is a novel binding partner of the tumor suppressor p53 and regulates its activity PMID: 25614517
9. Our results suggest for the first time that REV1 and REV3L SNPs might serve as potential predictive markers of outcome of cisplatin-based chemotherapy PMID: 24956248
10. Structural studies suggest the possible involvement of XRCC1 and its associated repair factors, REV1 in post replication repair. PMID: 24409475
11. The results show that human Rev1 disrupts G4 DNA structures and prevents refolding in vitro. PMID: 24366879
12. the first structural insights into the regulation of human Rev1 for TLS polymerases. PMID: 23220741
13. Rev1 but not Poleta depletion is epistatic to the lack of PCNA ubiquitination. PMID: 23761444
14. a structural basis for understanding the recognition of the Rev1-CT by Y-family DNA polymerases PMID: 22691049
15. Findings indicate that miR-96 regulates DNA repair and chemosensitivity by repressing RAD51 and REV1. PMID: 22761336
16. Results suggest that abasic sites might be bypassed by single B- and Y-family pols or combinations, possibly by REV1 and pols iota, eta, and delta/PCNA at the insertion step opposite the lesion and by pols eta and delta/PCNA at the subsequent extension step. PMID: 20888339
17. REV7 subunit of pol zeta mediated the interaction between REV3 and the REV1 C terminus. PMID: 22303021
18. FAAP20 binding stabilizes Rev1 nuclear foci and promotes interaction of the Fanconi anemia core with PCNA-Rev1 DNA damage bypass complexes. PMID: 22266823
19. Hsp90 promotes folding of REV1 into a stable and/or functional form(s) to bind to monoubiquitinated proliferating cell nuclear antigen in the regulation of translesion DNA synthesis-mediated mutagenesis PMID: 21690293
20. WRN facilitates REV1-dependent translesion synthesis. PMID: 20691646
21. the interaction between REV7 and REV3 creates a structural interface for REV1 binding PMID: 20164194
22. REV1 and Polzeta facilitate repair of interstrand cross-links independently of PCNA monoubiquitination and Poleta, whereas RAD18 plus Poleta, REV1, and Polzeta are all necessary for replicative bypass of cisplatin intrastrand DNA cross-links. PMID: 20028736
23. The results suggest that the positive charge on R357 could prevent interaction of REV1 with dGTP. PMID: 20059978
24. UV-induced mutant frequencies at the HPRT locus were reduced up to 75% in cells with reduced levels of REV1 mRNA and data support that targeting the mutagenic translesion DNA replication pathway can greatly reduce the frequency of induced mutations. PMID: 12930947
25. REV1 interacts with three Y-family DNA polymerases. PMID: 15189446
26. REV1 interacts with pol eta in translesion synthesis of damaged DNA PMID: 15380106
27. REV1-dependent processes are important determinants of cisplatin-induced genomic instability and the development of resistance. PMID: 16495473
28. a novel biochemical activity of human REV1 protein, due to higher affinity for single-stranded DNA (ssDNA) than the primer terminus PMID: 16803901
29. Rev1 is a polypeptide associated with Poleta. The study results suggest that arrested replication forks strengthen interactions among Poleta, Rad18/Rad6 and Rev1, consistent with the requirement for effective TLS by Poleta at sites of DNA lesions. PMID: 16824193
30. Results support Phe257Ser and Ser257Ser genotypes are associated with a decreased risk for cervical carcinoma, while Asn373Ser and Ser373Ser genotypes increased the risk. PMID: 18470628
31. Data show that PCNA ubiquitination and REV1 play distinct roles in the coordination of DNA damage bypass that are temporally separated relative to replication fork arrest. PMID: 18498753
32. human REV1, apparently the slowest Y family polymerase, is kinetically highly tolerant to N(2)-adduct at G but not to O(6)-adducts. PMID: 18591245
33. plays a role in mutagenesis and translesin DNA synthesis. (review) PMID: 18975621
34. Poleta-REV1 interactions prevent spontaneous mutations, probably by promoting accurate translesion DNA synthesis past endogenous DNA lesions PMID: 19157994
35. Novel structural features are important for providing Rev1 greater latitude in promoting efficient and error-free translesion DNA synthesis through the diverse array of bulky and potentially carcinogenic N(2)-deoxyguanosine DNA adducts in human cells. PMID: 19464298

Show More

Hide All

HGNC: 14060

OMIM: 606134

KEGG: hsa:51455

STRING: 9606.ENSP00000258428

UniGene: Hs.443077